ArticleOral oncology2022

Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Anti-invasive therapeutic in Head and neck squamous cell carcinoma.

Jessica L Allen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.